PharmAbcine Inc
208340
Company Profile
Business description
PharmAbcine Inc is a clinical stage biotech company that develops fully human therapeutic monoclonal antibody (mAb) using innovative discovery technology and excellent human resources for the treatment of human diseases, such as cancer and inflammatory diseases.
Contact
70, 2, 2nd Floor, KT Daedeok 2 Research Center
Jeonmin-dong
Yuseong-dong
Daejeon Metropolitan City1689
KORT: +82 428632017
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
33
Stocks News & Analysis
stocks
Is this ASX share a long-term buy?
Current operating conditions are challenging but over the long-term prospects are better.
stocks
Why Guzman and Reece's share reversals have a lot in common
Investors must weigh exciting growth stories against competitive dynamics and the price they are being asked to pay.
stocks
Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?
Watching the data centre business and the debate around it, here’s what we think of Nvidia stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,477.30 | 20.70 | -0.24% |
| CAC 40 | 8,137.26 | 86.19 | 1.07% |
| DAX 40 | 22,732.24 | 321.97 | 1.44% |
| Dow JONES (US) | 43,758.96 | 137.80 | 0.32% |
| FTSE 100 | 8,722.03 | 53.36 | 0.62% |
| HKSE | 23,787.93 | 753.91 | 3.27% |
| NASDAQ | 19,196.80 | 170.41 | 0.90% |
| Nikkei 225 | 38,142.37 | 95.42 | -0.25% |
| NZX 50 Index | 12,452.46 | 145.19 | 1.18% |
| S&P 500 | 5,991.45 | 36.20 | 0.61% |
| S&P/ASX 200 | 8,240.70 | 11.20 | -0.14% |
| SSE Composite Index | 3,380.21 | 34.17 | 1.02% |